CR Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CR Pharma
Largest movements
- Current investments -€250,000
down €250,000 (-100.0%), from €250,000 to €0
- Cash +€181,084
up €181,084 (+405.1%), from €44,698 to €225,782
mainly Current investments (+€250,000) and Net result for the year (+€189,849)
- Debts after one year -€140,004
down €140,004 (-11.9%), from €1.2m to €1.0m
- Reserves +€59,849
up €59,849 (+40.1%), from €149,137 to €208,986
- Other debts +€31,374
up €31,374 (+26.5%), from €118,290 to €149,664
- Gross operating margin +€197,610
up €197,610 (+221.6%), from €89,163 to €286,773
- Taxes +€43,966
up €43,966 (+313.6%), from €14,020 to €57,985
- Financial charges +€13,257
up €13,257 (+49.3%), from €26,897 to €40,154
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,213,482 | €2,157,354 | -€56,128 | -2.5% |
| Fixed assets | 21/28 | €1,901,609 | €1,916,241 | +€14,631 | +0.8% |
| Tangible fixed assets | 22/27 | €1,609 | €1,007 | -€603 | -37.4% |
| Furniture and vehicles | 24 | €1,609 | €1,007 | -€603 | -37.4% |
| Financial fixed assets | 28 | €1,900,000 | €1,915,234 | +€15,234 | +0.8% |
| Current assets | 29/58 | €311,872 | €241,113 | -€70,759 | -22.7% |
| Amounts receivable within one year | 40/41 | €15,744 | €15,125 | -€619 | -3.9% |
| Trade receivables | 40 | €15,744 | €15,125 | -€619 | -3.9% |
| Other amounts receivable | 41 | €0 | - | = | |
| Current investments | 50/53 | €250,000 | €0 | -€250,000 | -100.0% |
| Cash at bank and in hand | 54/58 | €44,698 | €225,782 | +€181,084 | +405.1% |
| Deferred charges and accrued income | 490/1 | €1,431 | €206 | -€1,224 | -85.6% |
| Total equity and liabilities | 10/49 | €2,213,482 | €2,157,354 | -€56,128 | -2.5% |
| Equity | 10/15 | €753,137 | €812,986 | +€59,849 | +7.9% |
| Contributions | 10/11 | €604,000 | €604,000 | = | 0.0% |
| Reserves | 13 | €149,137 | €208,986 | +€59,849 | +40.1% |
| Distributable reserves | 133 | €149,137 | €208,986 | +€59,849 | +40.1% |
| Profit (loss) carried forward | 14 | €0 | €0 | = | |
| Amounts payable | 17/49 | €1,460,345 | €1,344,368 | -€115,977 | -7.9% |
| Amounts payable after more than one year | 17 | €1,178,327 | €1,038,323 | -€140,004 | -11.9% |
| Financial debts | 170/4 | €1,178,327 | €1,038,323 | -€140,004 | -11.9% |
| Amounts payable within one year | 42/48 | €281,428 | €305,745 | +€24,317 | +8.6% |
| Current portion of amounts payable after more than one year | 42 | €140,004 | €140,004 | = | 0.0% |
| Trade debts | 44 | €1,187 | €966 | -€221 | -18.6% |
| Suppliers | 440/4 | €1,187 | €966 | -€221 | -18.6% |
| Taxes, remuneration and social security | 45 | €21,946 | €15,110 | -€6,836 | -31.1% |
| Taxes | 450/3 | €20,646 | €13,810 | -€6,836 | -33.1% |
| Remuneration and social security | 454/9 | €1,300 | €1,300 | = | 0.0% |
| Other amounts payable | 47/48 | €118,290 | €149,664 | +€31,374 | +26.5% |
| Accrued charges and deferred income | 492/3 | €590 | €300 | -€290 | -49.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €591 | €603 | +€12 | +2.0% |
| Other operating charges | 640/8 | €501 | €915 | +€414 | +82.8% |
| Non-recurring operating charges | 66A | €53 | €150 | +€97 | +183.0% |
| Gross operating margin | 9900 | €89,163 | €286,773 | +€197,610 | +221.6% |
| Operating profit (loss) | 9901 | €88,019 | €285,106 | +€197,087 | +223.9% |
| Financial income | 75/76B | €5,537 | €2,883 | -€2,654 | -47.9% |
| Recurring financial income | 75 | €5,537 | €2,883 | -€2,654 | -47.9% |
| Financial charges | 65/66B | €26,897 | €40,154 | +€13,257 | +49.3% |
| Recurring financial charges | 65 | €26,897 | €40,154 | +€13,257 | +49.3% |
| Profit (loss) for the period before taxes | 9903 | €66,659 | €247,835 | +€181,176 | +271.8% |
| Income taxes | 67/77 | €14,020 | €57,985 | +€43,966 | +313.6% |
| Profit (loss) for the period | 9904 | €52,639 | €189,849 | +€137,210 | +260.7% |
| Profit (loss) for the period to be appropriated | 9905 | €52,639 | €189,849 | +€137,210 | +260.7% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 10 October 2026 via checked.be.